E. Choong

Type de document

Articles (13) Recensions (1) Colloques et conférences (1)

Co-auteur

Date

Source

Mot-clé

Patients (9) Patients (9) Treatment (7) Drug monitoring (7) plasma (7) Development (6) Human beings (6) poids (5) thérapie (5) pharmacocinétique (5) Therapeutics (5) Psychotherapy patients (5) Population (5) Pharmacokinetics (5) Drugs (5) Weight (5) Population (5) Pharmacokinetics (5) protéine (4) association (4) surveillance (4) analyse (4) santé (4) effet (4) méthode (4) analyse (4) adulte (4) Monitoring (4) Social groups (4) Psychotropic drugs (4)

Documents écrit par E. Choong (14) | parle de E. Choong (0)

Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
J. Tachet et al. (15 nov. 2023)
Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
E. Choong et al. (11 août 2022)
Development of an assay by liquid chromatography coupled to tandem mass spectrometry for thiopurines drugs in whole blood and application for their Therapeutic Drug Monitoring
N. Nguyen et al. (1 juin 2022)
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
P. Thoueille et al. (2 févr. 2022)
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
L.A. Decosterd et al. (10 nov. 2020)
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
P. Courlet et al.
Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.
K. Dao et al.
Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments.
N. Saigi-Morgui et al. (2015)
Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression.
A. Delacrétaz et al. (2015)
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments.
L. Quteineh et al. (2015)
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
F. Vandenberghe et al. (2015)
Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.
F. Vandenberghe et al. (2015)
Pharmacogenetic Study on Risperidone Long-Acting Injection: Influence of Cytochrome P450 2D6 and Pregnane X Receptor on Risperidone Exposure and Drug-Induced Side-Effects.
E. Choong et al. (2013)
Influence of CRTC1 Polymorphisms on Body Mass Index and Fat Mass in Psychiatric Patients and the General Adult Population.
E. Choong et al. (2013)